First chlamydia vaccine tested in humans shows early promise

The first chlamydia vaccine to be tested in humans has been shown to be safe, and may protect against the most common sexually transmitted bacterial infection in the world.

Research teams in Denmark and the United Kingdom reported findings Monday from their phase one clinical trial in The Lancet Infectious Diseases.

“Of course, the research is still in its early days,” said study author Frank Follmann, director of the department of infectious disease immunology at Statens Serum Institut in Denmark. “But we’re very happy. We found a robust response.”

His team tested the vaccine in 35 women who were not infected with chlamydia. Some received a placebo.

Every single woman who got the vaccine showed an immune response, compared to none of the women who got the placebo shot.

“We hope this will be the first of many trials, so we can measure efficacy in the real world,” Follmann told NBC News.

It does not yet prove the vaccine will be effective in preventing transmissions. Right now, the best method of prevention is the proper use of condoms.